UPM Acquires Former Pfizer Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

UPM Acquires Former Pfizer Facility
Pfizer had gained the facility through its previous acquisition of King Pharmaceuticals.


UPM Pharmaceuticals, a Baltimore, Maryland-based drug development and contract manufacturer, will be acquiring the 500,000-ft2 commercial manufacturing facility that Pfizer currently operates in Bristol, Tennessee.

The acquisition of the Pfizer facility will provide UPM with large-scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules as well as semisolid manufacturing of creams and ointments. The facility will also provide for technology-transfer support, pilot-plant scale-up capabilities, analytical and microbial testing as well as dedicated suites for potent compounds. As part of the purchase, UPM will continue to manufacture Pfizer’s current portfolio of products within the facility for two years. The new facility will give UPM the capability to annually produce 3.5 billion tablets and 680 million capsules.

Pfizer gained the facility as part of its acquisition of King Pharmaceuticals, a deal which was announced in late 2010 and completed in early 2011. King Pharmaceuticals was founded by UPM’s current Chairman and CEO John Gregory.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here